

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Insulin aspart (Novolog[®])

Initiation (new start) criteria: Non-formulary **insulin aspart (Novolog) or its unbranded biologic (insulin aspart)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Type 2 diabetes mellitus with a documented allergy or intolerance* to regular insulin AND insulin lispro
- OR-**
- Diagnosis of Type 1 diabetes mellitus or Type 2 diabetes mellitus with insulinopenia[^] with a documented allergy or intolerance* to insulin lispro

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **insulin aspart (Novolog) or its unbranded biologic (insulin aspart)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Type 2 diabetes mellitus with a documented allergy or intolerance* to regular insulin AND insulin lispro
- OR-**
- Diagnosis of Type 1 diabetes mellitus or Type 2 diabetes mellitus with insulinopenia[^] with a documented allergy or intolerance* to insulin lispro

* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

[^] Insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.